Objective 1: Expand the development and availability of molecular and analytic resources. |
- Initiate the Cancer Molecular Analysis Project to integrate molecular signatures, targets, and interventions.
|
$5.00 M |
- Complete the Mammalian Gene Collection for full-length human and mouse cDNAs.
|
$3.00 M |
- Continue to develop technologies relevant to discovering and measuring molecular signatures of cancer and precancer and the dissemination of technologies to the scientific community.
|
$1.00 M |
- Continue to develop biosensors for detecting human cancer and cancer development through the Unconventional Innovation Program.
|
$6.50 M |
- Extend the Genetic Annotation Initiative to identify new cancer related gene polymorphisms in defined populations, define key molecular pathways by thoroughly characterizing genetic variations on numerous gene and protein expression profiles, and develop human gene expression profiles from specific tissues with measured exposure times to study epigenetic targets and cell pathways that lead to tumor formation.
|
$3.00 M |
TOTAL |
$18.5 M |
Objective 2: Establish and make available to researchers tissue resources to maximize the practical application of molecular signatures to problems in cancer research. |
- Establish a national tissue resource system for all major cancers, including lung, breast, prostate, colon, head and neck, brain, soft tissue, blood, bone, the gynecologic and genitourinary, and childhood malignancies.
|
$4.00 M |
- Expand tissue repositories of precancerous lesions in all major cancers.
|
$4.00 M |
- Use Phased Innovation Awards to develop tissue preservation and sample preparation methods to increase their utility and compatibility with new research technologies.
|
$4.00 M |
- Enhance the Web-based system to query pathology information systems, including pathology standardization and agreement on common data elements.
|
$2.50 M |
TOTAL |
$14.5 M |
Objective 4: Support new approaches for early detection of cancer and to determine biomarkers of precancerous lesions. |
- Identify easy-to-sample sites remote from the tumor itself, for more cost-effective, earlier cancer detection and risk assessment.
|
$2.00 M |
- Study molecular signatures to discover the causes of cancer, including infectious and environmental agents.
|
$1.00 M |
- Identify and validate biomarkers to develop effective, reliable tools for early cancer detection and to assess their potential for predicting cancer.
|
$2.00 M |
- Develop a program that uses the patterns of very small proteins in serum for early diagnosis of prostate, breast and ovarian cancer. Expand marker identification to predict disease stage and risk of recurrence.
|
$2.00 M |
- Expand studies to identify and validate epigenetic markers of cancer.
|
$1.00 M |
- Develop applied algorithms and statistical methods to analyze multiple biomarkers and patterns of molecular changes and link those changes with clinical outcomes.
|
$1.00 M |
- Develop analytical prediction tools for risk assessment, incorporating molecular, genetic, and family history information.
|
$1.00 M |
- Implement within the Early Detection Research Network, a Network-Wide Knowledge and Informatics Center.
|
$1.00 M |
TOTAL |
$11.0 M |